Jaiman Manasi 4
4 · Aardvark Therapeutics, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Aardvark (AARD) CMO Manasi Receives 70,549-Share Award
What Happened
Jaiman Manasi, Chief Medical Officer of Aardvark Therapeutics (AARD), received a grant of 70,549 derivative shares on February 9, 2026. The reported price is $0.00, so there was no cash paid or received at the time of the grant. This transaction is an award/grant (derivative security), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (filed within the typical 2-business-day window).
- Transaction type/code: A (award/grant) of derivative securities.
- Shares involved: 70,549 derivative shares granted at $0.00 (no immediate proceeds).
- Vesting: Per footnote — 1/4 vests on Feb 9, 2027, then 1/48 vests monthly thereafter, contingent on continued service.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- No indication this was a 10b5-1 sale, cashless exercise, gift, or tax-withholding event in the provided details.
Context
This is a standard equity compensation grant tied to continued service (vesting over time). Because it’s a derivative award with a vesting schedule, there’s no immediate sale or market impact from this filing. Such grants are common as part of executive compensation and do not by themselves indicate a buy/sell signal.
Insider Transaction Report
- Award
Stock option (right to buy)
[F1]2026-02-09−70,549→ 70,549 totalExercise: $13.48Exp: 2036-02-09→ Common Stock (70,549 underlying)
Footnotes (1)
- [F1]1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.